James L. Januzzi Jr., MD
CHICAGO — Nearly half of patients who withdrew from pharmacological HF therapy and were considered as being recovered from dilated cardiomyopathy relapsed, according to data presented at the American Heart Association Scientific Sessions.
“Withdrawal of therapy should not usually be advised to our patients at least until we can predict who is going to relapse and who is not and we have a better understanding of therapies that may be able to be reduced and the importance of the different therapies,” Brian Halliday, MBChB, PhD, clinical lecturer in cardiology at Imperial College in London, said during a press conference.
This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.
Search Healio's robust listing of national and international medical meetings.
Tell us what you think about Healio.com »
Get the latest news and education delivered to your inbox
©2018 Healio All Rights Reserved.